Labaran Waya

Metastatic maganin kansar mahaifa yanzu an amince da shi

Written by edita

A yau sanofi-aventis Canada Inc. (Sanofi) ya sanar da amincewar Libtayo® (cemiplimab) don kula da manya masu fama da ciwon daji na mahaifa waɗanda suka ci gaba a kan ko bayan maganin cutar sankara na platinum kuma waɗanda ke buƙatar ƙarin tsarin tsarin magani don magance maimaitawa ko metastatic. cuta. Amincewar ta dogara ne akan Nazarin 3 EMPOWER-Cervical 1 na Cemiplimab a cikin Manya Tare da Ciwon Sankara (NCT03257267). Gwajin, wanda shine gwajin asibiti mafi girma da aka yi bazuwar a cikin ci gaban ciwon daji na mahaifa, ya haɗa da marasa lafiya da ke fama da cutar kansa mai maimaitawa ko metastatic wanda tarihinsa ya kasance ko dai squamous cell carcinoma ko adenocarcinoma. An keɓance mahalarta don karɓar ko dai cemiplimab ko zaɓin chemotherapy na mai binciken. Babban abin ƙarshe na gwajin shine gaba ɗaya tsira.             

Mark Surka, Ph.D, Shugaban Likitan Oncology, Sanofi Kanada: "Yayin da adadin ciwon sankarar mahaifa a Kanada yana godiya ga raguwa, saboda tasirin maganin rigakafin HPV don hana cutar sankarar mahaifa daga formingiii, Kanada har yanzu tana ganin 1400. matan da ke fama da wannan cuta a kowace shekara kuma suna buƙatar zaɓuɓɓukan magani. Muna alfahari da kawowa Libtayo amincewa ga matan da suka kamu da cutar sankarar mahaifa ko kuma masu saurin kamuwa da cutar kansa, da kuma kwararrun likitocin da ke kula da su.”

Alamu ta huɗu ga Libtayo a cikin wahalar magance cututtukan daji

Tare da sanarwar ta yau, yanzu an amince da Libtayo azaman zaɓi na rigakafi don cututtukan daji guda huɗu:

• A cikin Afrilu 2019, Libtayo ya zama zaɓi na farko na rigakafi a cikin Kanada ga manya masu fama da cutar sankarau ko kuma ci gaban cutaneous squamous cell carcinoma (CSCC) waɗanda ba 'yan takara ba ne don aikin tiyatar warkewa ko radiation na warkewa.

• A cikin Oktoba 2021, an faɗaɗa samuwar Libtayo don haɗawa da manya waɗanda ke da ci-gaban ciwon huhu mara ƙanƙanta da ke bayyana PD-L1 a cikin ≥ 50% na ƙwayoyin tumor (Tumour Proportion Score [TPS] ≥ 50%), kamar yadda aka ƙaddara ta ingantacciyar hanya. gwajin, ba tare da EGFR, ALK ko ROS1 aberrations waɗanda suka sami ci gaba NSCLC a cikin gida waɗanda ba 'yan takarar neman aikin tiyata ba ko tabbataccen chemoradiation, ko metastatic NSCLC.

Har ila yau, a cikin Oktoba na 2021, an amince da Libtayo don kula da manya masu ciwon daji na basal cell carcinoma (BCC) a baya da aka yi da shi tare da mai hana hanyar bushiya (HHI).

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...